Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Compositions and methods of use of A2 adenosine receptor (AR) agonists for treating conditions modulated by A2A and A2B ARs including myocardial ischemia, reperfusion injury, cystic fibrosis, erectile dysfunction, inflammation, restenosis and septic shock More
Protection against tissue injury from a variety of causes More
Modified cells of the mononuclear phagocyte system over-expressing neutrophil gelatinase-associated lipocalin can be used to prevent and treat ischemia, acute failure and transplant rejection by reducing inflammation and promoting tissue regeneration More
Related Reports
Market Research Reports provided by reports.iptechex.com
Nov 2010 - 50 pages - $500
May 2011 - 52 pages - $1,000
Nov 2010 - 40 pages - $500
Jan 2011 - 30 pages - $500
Dec 2010 - 51 pages - $1,000
Jun 2006 - 952 pages - $2,495
Jul 2011 - 72 pages - $500
May 2011 - 75 pages - $500
Aug 2011 - 7 pages - $75
Aug 2011 - 7 pages - $75
Your selection
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us